Collection
Curated by Dr. Joseph G. Pressey From 5 sources across the library

Pediatric Sarcoma Essentials

items total cited expert statements Updated Nov 17, 2026
Start exploring
Try
Intelligent Search· answers come only from this collection · not medical advice
Content of this collection items

Radiation decisions in young children involve nuanced discussions of toxicities including pulmonary function, cardiac exposure, wound healing, and chest wall development, individualized case by case — Luke Pater, Clinical & Research Update: Sarcoma w/ Drs. Roshni Dasgupta, Joseph Pressey, Arthur Meyer, Luke Pater · 1:01:48

Clinical & Research Update: Sarcoma w/ Drs. Roshni Dasgupta, Joseph Pressey, Arthur Meyer, Luke Pater
This video presents a detailed clinical and research update on pediatric sarcomas from Cincinnati Children's, featuring a multidisciplinary team: with Drs. Roshni Dasgupta, Joseph Pressey, Arthur Meyers, & Luke Pater. It covers two complex
video1:06:24 · Sep 2026
Watch →
Pediatric Ewing Sarcoma Chemotherapy: What's Actually Changed Since the 1990s? w/ Dr. Joseph Pressey
Dr. Joseph Pressey, a Pediatric Oncologist at Cincinnati Children's, discusses the current standard of care for Ewing sarcoma chemotherapy. He explains that the AEWS0031 Regimen B, involving 14 cycles of VDC/IE, remains the established prot
video0:21 · Nov 2026
Watch →
The Challenges of Cancer Therapy in Adolescents and Young Adults
Adolescents and young adults with cancer face a unique set of challenges and fare worse than kids with some of the same types of cancers.
article · Nov 2026
Read →
Challenges in the Treatment of Sarcomas of Adolescents and Young Adults
Adolescent and young adult (AYA) sarcoma patients do not fare as well as their younger counterparts. A variety of factors theorized to underlie such disparate outcomes have been identified including distinct tumor and host biology. Compared
article · Nov 2026
Read →
Current concepts on the surgical and medical management of osteosarcoma.
Although advances have been made in both surgical and medical management of patients with osteosarcoma, the overall survival of patients with osteosarcoma has remained constant, with no substantial improvement in the past 15 years. Advances
article · Nov 2026
Read →

Head and neck rhabdomyosarcoma lymph node staging is challenging due to varied patterns of lymphatic drainage and the suboptimal predictive value of available imaging modalities. Sentinel lymph node biopsy in head and neck rhabdomyosarcoma

Molecular Pathogenesis6 items
Molecular pathogenesis of rhabdomyosarcoma
Rhabdomyosarcoma (RMS) is a family of soft tissue tumors that are associated with the skeletal muscle lineage and generally occur in the pediatric population. Based on histopathologic features, two subtypes, embryonal (ERMS) and alveolar (A
article · Nov 2026
Read →
2D-difference gel electrophoretic proteomic analysis of a cell culture model of alveolar rhabdomyosarcoma
To evaluate the consequences of expression of the protein encoded by PAX3-FOXO1 (P3F) in the pediatric malignancy alveolar rhabdomyosarcoma (A-RMS), we developed and evaluated a genetically defined in vitro model of A-RMS tumorigenesis. The
article · Nov 2026
Read →
FOXF1 is required for the oncogenic properties of PAX3-FOXO1 in rhabdomyosarcoma
The PAX3-FOXO1 fusion protein is the key oncogenic driver in fusion positive rhabdomyosarcoma (FP-RMS), an aggressive soft tissue malignancy with a particularly poor prognosis. Identifying key downstream targets of PAX3-FOXO1 will provide n
article · Nov 2026
Read →
Hedgehog pathway activity in pediatric embryonal rhabdomyosarcoma and undifferentiated sarcoma: a report from the Children's Oncology Group
Background: Aberrant activation of the hedgehog (Hh) signaling pathway is implicated widely in both pediatric and adult malignancies. Inactivation of the Hh regulator PTCH is responsible for the Gorlin cancer predisposition syndrome. The sp
article · Nov 2026
Read →
GLI inhibitor GANT-61 diminishes embryonal and alveolar rhabdomyosarcoma growth by inhibiting Shh/AKT-mTOR axis
Rhabdomyosarcoma (RMS) typically arises from skeletal muscle. Currently, RMS in patients with recurrent and metastatic disease have no successful treatment. The molecular pathogenesis of RMS varies based on cancer sub-types. Some embryonal
article · Nov 2026
Read →
Rapamycin targeting mTOR and hedgehog signaling pathways blocks human rhabdomyosarcoma growth in xenograft murine model
Rhabdomyosarcomas (RMS) represent the most common childhood soft-tissue sarcoma. Over the past few decades outcomes for low and intermediate risk RMS patients have slowly improved while patients with metastatic or relapsed RMS still face a
article · Nov 2026
Read →
Treatment & Targeted Therapy3 items
Pediatric Anaplastic Embryonal Rhabdomyosarcoma: Targeted Therapy Guided by Genetic Analysis and a Patient-Derived Xenograft Study
Therapy for rhabdomyosarcoma (RMS) has generally been limited to combinations of conventional cytotoxic agents similar to regimens originally developed in the late 1960s. Recently, identification of molecular alterations through next-genera
article · Nov 2026
Read →
Targeting wild-type and mutant p53 with small molecule CP-31398 blocks the growth of rhabdomyosarcoma by inducing reactive oxygen species-dependent apoptosis
Rhabdomyosarcoma (RMS) is a common soft-tissue sarcoma of childhood in need of more effective therapeutic options. The expression of p53 in RMS is heterogeneous such that some tumors are wild-type whereas others are p53 mutant. The small mo
article · Nov 2026
Read →
CD133 marks a myogenically primitive subpopulation in rhabdomyosarcoma cell lines that are relatively chemoresistant but sensitive to mutant HSV.
Rhabdomyosarcoma (RMS) is characterized by features of skeletal muscle and is comprised of two major histological subtypes, embryonal (E-RMS), and alveolar (A-RMS). Subsets of each RMS subtype demonstrate resistance to multimodal therapy le
article · Nov 2026
Read →
Surgical Management1 item
Sentinel lymph node biopsy in head and neck rhabdomyosarcoma
Head and neck rhabdomyosarcoma lymph node staging is challenging due to varied patterns of lymphatic drainage and the suboptimal predictive value of available imaging modalities. Furthermore, regional relapse rates are unacceptably high, an
article · Nov 2026
Read →

Chemotherapy-induced thrombocytopenia was defined as a failure to achieve 75,000 platelets per microliter by day 21 after the start of any chemotherapy cycle. Chemotherapy-induced thrombocytopenia in Ewing sarcoma: Implications and potential for romiplostim supportive care

Chemotherapy & Treatment2 items
Chemotherapy-induced thrombocytopenia in Ewing sarcoma: Implications and potential for romiplostim supportive care
Background: Maintaining dose-dense, interval-compressed chemotherapy improves survival in patients with Ewing sarcoma but is limited by myelosuppression. Romiplostim is a thrombopoietin receptor agonist that may be useful in the treatment o
article · Nov 2026
Read →
Results of a Randomized, Double-Blinded, Placebo-Controlled, Phase 2.5 Study of Saracatinib (AZD0530), in Patients with Recurrent Osteosarcoma Localized to the Lung
Purpose: Osteosarcoma is a rare cancer and a third of patients who have completed primary treatment will develop osteosarcoma recurrence. The Src pathway has been implicated in the metastatic behavior of osteosarcoma; about 95% of samples e
article · Nov 2026
Read →
Molecular Targets2 items
Molecularly Defined Subsets of Ewing Sarcoma Tumors Differ in Their Responses to IGF1R and WEE1 Inhibition
Purpose: Targeted cancer therapeutics have not significantly benefited patients with Ewing sarcoma with metastatic or relapsed disease. Understanding the molecular underpinnings of drug resistance can lead to biomarker-driven treatment sele
article · Nov 2026
Read →
Targeting EYA3 in Ewing Sarcoma Retards Tumor Growth and Angiogenesis
EWSR1/FLI1, the most common fusion gene in Ewing sarcoma, upregulates expression of the Eyes Absent 3 (EYA3) transactivator-phosphatase protein. The purpose of this study was to investigate molecular and cellular mechanisms through which EY
article · Nov 2026
Read →
Rare Presentations1 item
Primary Ewing sarcoma of the brain: a case report and literature review
Ewing sarcoma, along with peripheral primitive neuroectodermal tumor, belongs to a tumor family that shares clinicopathologic and molecular genetic features, including the characteristic chromosomal translocation that results in the fusion
article · Nov 2026
Read →

POT1 tumor predisposition is associated with a spectrum of malignancies due to loss of function mutations in POT1 leading to telomere elongation and genomic instability. Dramatic multifocal osteosarcoma treatment response in the setting of POT1 tumor predisposition syndrome

Treatment Strategies2 items
Zoledronic acid in metastatic osteosarcoma: encouraging progression free survival in four consecutive patients.
Zoledronic acid (ZA) is a third-generation bisphosphonate in widespread clinical use to reduce pain and skeletal events in patients from a variety of malignancies with bone metastases. Pre-clinical studies indicate that ZA inhibits osteosar
article · Nov 2026
Read →
Dramatic multifocal osteosarcoma treatment response in the setting of POT1 tumor predisposition syndrome
Introduction: POT1 tumor predisposition (POT1-TPD) is associated with a spectrum of malignancies due to loss of function mutations in POT1 leading to telomere elongation and genomic instability. Osteosarcoma is the most common primary malig
article · Nov 2026
Read →
Targeted Therapy1 item

Constitutively active RAS-GTP and increased MAPK signaling are important in tumorigenesis in neurofibromatosis type 1 and malignant peripheral nerve sheath tumors. Targeted Inhibition of the Dual Specificity Phosphatases DUSP1 and DUSP6 Suppress MPNST Growth via JNK.

NF1-Related MPNST3 items
Targeting Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors (MPNST) in a Phase II Study of Everolimus in Combination with Bevacizumab (SARC016)
Purpose: There are no known effective medical treatments for refractory MPNST. Inactivation of the NF1 tumor suppressor in MPNST results in upregulation of mTOR (mammalian target of rapamycin) signaling and angiogenesis, which contributes t
article · Nov 2026
Read →
Malignant peripheral nerve sheath tumor development during MEK inhibitor treatment: A pre-clinical study and a clinical case series.
People with Neurofibromatosis type 1 (NF1) are at risk of developing benign and malignant peripheral nerve sheath tumors (MPNST). In NF1, the overall lifetime risk of MPNST is estimated at 8%-13%, with increased risk associated with specifi
article · Nov 2026
Read →
Malignant peripheral nerve sheath tumor: Transformation in a patient with neurofibromatosis type 2
Malignant peripheral nerve sheath tumor (MPNST) is a rare soft-tissue sarcoma with an unfavorable prognosis and limited therapeutic options. MPNSTs can be sporadic, but are often associated with neurofibromatosis (NF) 1 and usually arise fr
article · Nov 2026
Read →
Molecular Targets1 item
Targeted Inhibition of the Dual Specificity Phosphatases DUSP1 and DUSP6 Suppress MPNST Growth via JNK.
In neurofibromatosis type 1 (NF1) and in highly aggressive malignant peripheral nerve sheath tumors (MPNSTs), constitutively active RAS-GTP and increased MAPK signaling are important in tumorigenesis. Dual specificity phosphatases (DUSPs) a
article · Nov 2026
Read →

The primary endpoint was investigator-assessed objective response rate measured according to the Response Evaluation Criteria in Solid Tumors, version 1.1. Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study

Epithelioid Sarcoma1 item
Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study
Background: Epithelioid sarcoma is a rare and aggressive soft-tissue sarcoma subtype. Over 90% of tumours have lost INI1 expression, leading to oncogenic dependence on the transcriptional repressor EZH2. In this study, we report the clinica
article · Nov 2026
Read →
BCOR-Altered Sarcomas2 items
Strategies for the Treatment of Infantile Soft Tissue Sarcomas With BCOR Alterations
BCOR alterations are described in ultra-rare infantile soft tissue sarcomas including primitive myxoid mesenchymal tumor of infancy and undifferentiated round cell sarcoma (URCS). Previous reports often describe dismal outcomes. Thus, we un
article · Nov 2026
Read →
Successful Treatment of Recurrent Primitive Myxoid Mesenchymal Tumor of Infancy With BCOR Internal Tandem Duplication
Primitive myxoid mesenchymal tumor of infancy (PMMTI) is a rare tumor with 12 months after the conclusion of therapy. This case confirms BCOR ITD as a key finding in PMMTI. The therapeutic approach described here is similar to that used for
article · Nov 2026
Read →
CIC-Rearranged Sarcomas1 item
Clinicopathologic Features of a Series of Primary Renal CIC-rearranged Sarcomas With Comprehensive Molecular Analysis
CIC-rearranged sarcomas rarely occur in visceral organs including the kidney. The most common fusion partner with CIC is the DUX4 gene, but variant fusion partners have also been reported. Herein, we describe the clinicopathologic features
article · Nov 2026
Read →
Undifferentiated Sarcomas2 items

Image-guided percutaneous biopsy should be strongly considered the diagnostic modality of choice for pediatric bone and soft tissue tumors. — Sophia Schermerhorn, Pediatric and Young Adult Image-Guided Percutaneous Bone Biopsy-A New Standard of Care? · 0:56

Image-Guided Biopsy2 items
Pediatric and Young Adult Image-Guided Percutaneous Bone Biopsy-A New Standard of Care?
Jo Cooke-Barber, Joseph G Brungardt, Michael Sorger, Joseph G Pressey, Brian Turpin, Rajaram Nagarajan, Sara Szabo, Joel Sorger, Neil Johnson, Roshni DasguptaBackground: There are no consensus guidelines regarding the use of percutaneous ne
video1:05 · Feb 2026
Watch →
Sentinel Lymph Node Mapping2 items
Fluorescent-guided surgery and the use of indocyanine green sentinel lymph node mapping in the pediatric and young adult oncology population
Background: Technetium-99 (99m Tc) lymphoscintigraphy with blue dye injection is an accepted method for sentinel lymph node (SLN) mapping, but blue dye has known adverse effects, and injection of 99m Tc may increase time under anesthesia fo
article · Nov 2026
Read →
Detection of lymph node metastases in pediatric and adolescent/young adult sarcoma: Sentinel lymph node biopsy versus fludeoxyglucose positron emission tomography imaging-A prospective trial
Background: Lymph node metastases are an important cause of treatment failure for pediatric and adolescent/young adult (AYA) sarcoma patients. Nodal sampling is recommended for certain sarcoma subtypes that have a predilection for lymphatic
article · Nov 2026
Read →
Imaging2 items
MR Imaging of Pediatric Musculoskeletal Tumors:: Recent Advances and Clinical Applications.
Pediatric musculoskeletal tumors comprise approximately 10% of childhood neoplasms, and MR imaging has been used as the imaging evaluation standard for these tumors. The role of MR imaging in these cases includes identification of tumor ori
article · Nov 2026
Read →
Comparison of 0.3-mSv CT to Standard-Dose CT for Detection of Lung Nodules in Children and Young Adults With Cancer.
BACKGROUND. CT is the imaging modality of choice to identify lung metastasis. OBJECTIVE. The purpose of this study was to evaluate the performance of reduced-dose CT for the detection of lung nodules in children and young adults with cancer
article · Nov 2026
Read →

The five-year survival for patients with high-risk stage 4 neuroblastoma has not improved in two decades. Whole exome sequencing identified sixty-five coding mutations in four neuroblastoma tumors

Whole exome sequencing identified sixty-five coding mutations in four neuroblastoma tumors
Neuroblastoma is a pediatric tumor characterized by histologic heterogeneity, and accounts for ~15% of childhood deaths from cancer. The five-year survival for patients with high-risk stage 4 disease has not improved in two decades. We used
article · Nov 2026
Read →
Real-time genomic profiling of histiocytoses identifies early-kinase domain BRAF alterations while improving treatment outcomes
Many patients with histiocytic disorders such as Langerhans cell histiocytosis (LCH) or Erdheim-Chester disease (ECD) have treatment-refractory disease or suffer recurrences. Recent findings of gene mutations in histiocytoses have generated
article · Nov 2026
Read →
Using cancer phenotype sex-specificity to enable unbiased penetrance estimation of SMARCA4 pathogenic variants for small cell carcinoma of the ovary, hypercalcemic type (SCCOHT).
Small cell carcinoma of the ovary, hypercalcemic type (SCCOHT) is an extremely rare, highly aggressive cancer (mean age of onset, 24 years). Nearly all cases are associated with somatic or germline pathogenic variants (GPVs) in SMARCA4. Ear
article · Nov 2026
Read →

Pediatric and Young Adult Image-Guided Percutaneous Bone Biopsy-A New Standard of Care?
The study evaluated 169 biopsies in 141 patients over a 10-year period at a single institution.
Sophia Schermerhorn0:13
Nearly 90% of the biopsies were core-needle biopsies.
Sophia Schermerhorn0:19
All biopsies were performed with image guidance, most commonly CT, sometimes combined with fluoroscopy and ultrasound.
Sophia Schermerhorn0:22
All biopsies were performed by interventional radiologists.
Sophia Schermerhorn0:28
97.9% of biopsies were diagnostic.
Sophia Schermerhorn0:33
Only 3 patients required repeat biopsy.
Sophia Schermerhorn0:33
There was one patient with transient sciatic nerve paresis, which resolved.
Sophia Schermerhorn0:40
The complication rate was 0.7%.
Sophia Schermerhorn0:43
The approach provided sufficient tissue for histology, immunostains, and molecular studies.
Sophia Schermerhorn0:46
Immunostains and molecular studies are increasingly essential for modern risk stratification and targeted therapy.
Sophia Schermerhorn0:46
Image-guided percutaneous biopsy should be strongly considered the diagnostic modality of choice for pediatric bone and soft tissue tumors.
Expert opinionSophia Schermerhorn0:56
Clinical & Research Update: Sarcoma w/ Drs. Roshni Dasgupta, Joseph Pressey, Arthur Meyer, Luke Pater
Compressed-interval VDC/IE chemotherapy given every 2 weeks is now well proven to be of benefit over 3-week schedule for Ewing sarcoma
Joseph Pressey9:23
For chest wall sarcomas, the old adage of needing a rib above and a rib below for margins is not the case anymore; the goal is just to get negative margins if possible
Roshni Dasgupta11:23
When tumor is adherent to diaphragm or pericardium, you should not dissect these structures off the tumor because you don't know where the margin is; instead take a portion of the adherent structure with the tumor
Roshni Dasgupta12:18
Titanium rib reconstruction systems may need revision as the child grows, particularly during puberty with significant growth spurts
Roshni Dasgupta14:05
For Ewing sarcoma radiotherapy, treatment typically involves two phases: disease presentation volume and then more specific targeting of gross disease or positive margins
Luke Pater15:29
Protons are preferred over photons for focused boost volumes because they reduce low-dose exposure to non-target tissue beyond the target, though in lungs the benefit is compromised due to low-density tissue causing scatter
Luke Pater20:12
Small cell carcinoma of the ovary hypercalcemic type (SCCOHT) was originally described around 1980 in young adult women presenting with ovarian tumors with nondescript morphology, often associated with hypercalcemia
Joseph Pressey23:23
SCCOHT tumors are actually malignant rhabdoid tumors; some have postulated they should be called malignant rhabdoid tumor of the ovary
Joseph Pressey23:47
In 2014, three labs simultaneously identified SMARCA4 mutation (usually single nucleotide variant) as the underlying genetic defect in SCCOHT
Joseph Pressey24:06
SMARCA4 encodes BRG1 and its loss unifies all SCCOHT tumors; like Ewing sarcoma, these tumors have very low tumor mutational burden with SMARCA4 usually the only mutation found
Joseph Pressey24:40
Many SCCOHT patients enter the OR without this diagnosis in the differential; they are usually thought to be germ cell tumors, resulting in incomplete initial surgery
Joseph Pressey26:39
SCCOHT is a chemo-sensitive tumor but only transiently so; it is very important to start intensive systemic chemotherapy quickly rather than sending patients back for immediate second-look operation
Joseph Pressey27:00
The VPCBAE regimen (vinorelbine, cisplatin, cyclophosphamide, bleomycin, doxorubicin, etoposide) with all six agents given every 21-day cycle is very intensive toxic therapy requiring meticulous supportive care
Joseph Pressey27:20
Four cycles of VPCBAE induction chemotherapy are given prior to second-look operation for SCCOHT; patients with measurable disease after initial surgery often respond well even by RECIST criteria
Joseph Pressey27:43
The 12-month-old SCCOHT patient is the youngest ever described with this tumor; the average age for diagnosis is 24 years
Joseph Pressey28:25
MRIs and PET scans are not great for detecting peritoneal disease and very small nodules (1mm); second-look surgery is necessary to identify disease that imaging cannot detect
Roshni Dasgupta29:18
For SCCOHT second-look surgery, laparoscopy is used initially to understand extent of disease and determine size of laparotomy incision needed; the operation is never done with laparoscopy alone
Roshni Dasgupta29:44
Complete cytoreduction for SCCOHT includes removing all visible disease, with particular attention to peritoneal reflection in pouch of Douglas and surface of rectum where tumor can hide after spill
Roshni Dasgupta30:40
HIPEC in pediatric patients requires a multidisciplinary team experienced in this procedure; it is not the same as adult HIPEC
Roshni Dasgupta32:25
GCMD Library — Curated collection · summaries prepared automatically from the recordings · educational content, not medical advice
Start the course
We remember your choice for this collection.
Follow this collection We'll email you when something new is added to Pediatric Sarcoma Essentials — the new recordings themselves, with links. Nothing when nothing is added; every email has an unsubscribe link.